The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents.
 
Carl Zainaldin
No Relationships to Disclose
 
Sankalp Arora
No Relationships to Disclose
 
Sri Bathini
No Relationships to Disclose
 
Vishruti Pandya
No Relationships to Disclose
 
Sejong Bae
Consulting or Advisory Role - Syneos Health
 
Udita Gupta
No Relationships to Disclose
 
Sarah Worth`
Consulting or Advisory Role - Blueprint Medicines; CTI BioPharma Corp
 
Kimo Bachiashvili
No Relationships to Disclose
 
Ravi Bhatia
No Relationships to Disclose
 
Kelly Nicole Godby
No Relationships to Disclose
 
Omer Jamy
No Relationships to Disclose
 
Sravanti Rangaraju
No Relationships to Disclose
 
Barry Diamond
No Relationships to Disclose
 
Josh D Oliver
No Relationships to Disclose
 
Donna E. Salzman
No Relationships to Disclose
 
Antonio Di Stasi
No Relationships to Disclose
 
Pankit Vachhani
Consulting or Advisory Role - Abbvie; Amgen; Blueprint Medicines; CTI BioPharma Corp; Incyte; Jazz Pharmaceuticals; Novartis; Pfizer
Speakers' Bureau - Incyte
Research Funding - Abbvie (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Blueprint Medicines (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Gilead/Forty Seven (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Seagen (Inst); Takeda (Inst)